Private company

NovAccess Global Inc.

NovAccess Global Inc. is an American pharmaceutical preparations company, incorporated in Colorado.1 It is headquartered in Chagrin Falls, Ohio.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersChagrin Falls, Ohio1
  • Incorporated inCO2
  • Business address8584 E. Washington Street, No. 127, Chagrin Falls, Oh 440232
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

2020, we exited the solar business and focused all our efforts on our biopharmaceutical business.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue4567$0 in 2024
0$200.0K$400.0K$600.0K$800.0K2018: $665.0K$665.0K20182019: $0$020192020: $0$020202022: $0$020222023: $0$020232024: $0$02024
Gross profit4567$0 in 2024
0$100.0K$200.0K$300.0K2018: $226.3K$226.3K20182019: $0$020192020: $0$020202022: $0$020222023: $0$020232024: $0$02024
Operating income458967-$901.7K in 2024+346% since 2018
-$3.0M-$2.0M-$1.0M02018: -$202.3K-$202.3K20182019: -$544.7K-$544.7K2019+169%2020: -$828.9K-$828.9K2020+52%2021: -$2.7M-$2.7M2021+226%2022: -$1.4M-$1.4M2022−49%2023: -$2.5M-$2.5M2023+80%2024: -$901.7K-$901.7K2024−63%
Net income458967-$2.7M in 2024−33% since 2018
-$7.5M-$5.0M-$2.5M0$2.5M2018: -$4.0M-$4.0M20182019: $2.3M$2.3M20192020: -$6.8M-$6.8M20202021: -$2.5M-$2.5M2021−63%2022: -$1.7M-$1.7M2022−32%2023: -$4.7M-$4.7M2023+175%2024: -$2.7M-$2.7M2024−44%
Fiscal year2018201920202021202220232024
Revenue$665.0K4$05$05$06$07$07
Cost of revenue$438.7K4$05$05$06$07$07
Gross profit$226.3K4$05$05$06$07$07
Research and development$146.1K9$186.1K6$154.4K7$153.9K7
Selling, general and admin$428.3K4$544.7K5$828.9K8$2.6M9$1.2M6$2.3M7$747.8K7
Operating expenses$1.4M6$2.5M7$901.7K7
Operating income-$202.3K4-$544.7K5-$828.9K8-$2.7M9-$1.4M6-$2.5M7-$901.7K7
Interest$111.0K4$72.0K5$30.5K8$377.9K9$1.7M6$1.2M6
Income tax$04$05$08$09$06$07$07
Net income-$4.0M4$2.3M5-$6.8M8-$2.5M9-$1.7M6-$4.7M7-$2.7M7
Earnings per share-$0.004$1.505-$4.228-$0.229-$0.106-$0.237-$0.067
Earnings per share (diluted)-$0.229-$0.106-$0.237-$0.067
Shares (weighted, basic)16.5M shares620.8M shares744.6M shares7
Shares (weighted, diluted)16.5M shares620.8M shares744.6M shares7

Compare NovAccess Global Inc. with another company

Corporate structure

NovAccess Global Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NovAccess Global Inc.

  • AJB Capital Investments LLC Filed SC 13G/A on NovAccess Global Inc., latest Nov 18, 2024 (4 filings since May 17, 2022)
  • David Sumner Filed SC 13D on NovAccess Global Inc., latest Jun 11, 2024
  • Daniel G. Martin Filed SC 13D/A on NovAccess Global Inc., latest Mar 14, 2022
  • Dwain Morris-Irvin Filed SC 13D/A on NovAccess Global Inc., latest Mar 14, 2022
  • NovAccess Global Inc. Chagrin Falls, Ohio

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NovAccess Global Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$20.9K7 Sep 30, 2024$21.4K7 Sep 30, 2023−2.4%
Stakes in other companies (equity method)$07 Sep 30, 2024$07 Sep 30, 2023

Properties, in its own words

As a biopharmaceutical company in the pre-IND stage, NovAccess does not require a physical headquarters or permanent research and development facilities. To conserve capital, we utilize third-party office facilities when needed and maintain a mailing office address at 459 Columbus Ave #607, New York, NY 10025. In addition, our StemVax, LLC subsidiary utilizes third-party laboratory and research space in Pasadena and Santa Cruz, California as needed.

Item 2 of the 10-K filed Jan 14, 2026.3

Leadership

Who has led NovAccess Global Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel G. Martin2020
  2. Dwain Morris-Irvin2020–2022

President

  1. Tom M. Djokovich2008

Chief financial officer

  1. Jeff J. Huitt2008
  2. Larry Michael Yukich2020–2021
  3. Neil J. Laird2021–2023

Chief operating officer

  1. Joseph Grimes2007
2010201520202025
Board members and other officers (9)

Former names

  • XSUNX INCOct 2, 2003 to Aug 21, 20202
  • SUN RIVER MINING INCAug 15, 2000 to Aug 12, 20032

Timeline

  1. Sep 24, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares28
  2. Aug 1, 20248-K Executive or director change29
  3. Jun 4, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares30
  4. May 17, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares31
  5. May 3, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares32
  6. Feb 28, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares33
  7. Feb 6, 20248-K Debt or obligation accelerated34
  8. Jan 22, 20248-K Debt or obligation accelerated35
  9. Jan 5, 20248-K Entered a material agreement; New debt or obligation36
  10. Jan 2, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares37
  11. Dec 21, 20238-K New debt or obligation; Other events38
  12. Sep 11, 20238-K Other events39
  13. Nov 23, 2020New chief executive Dwain Morris-Irvin becomes CEO15
  14. Jun 10, 2020New chief executive Daniel G. Martin becomes CEO14

Filings

91 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 37 major events, 11 insider forms, 7 large holders, 22 other. The latest 20:

  1. Jan 14, 202610-K EDGAR
  2. Nov 18, 2024SC 13G/A SCHEDULE 13G AMENDMENT NO. 4 EDGAR
  3. Oct 31, 202410-Q EDGAR
  4. Sep 24, 20248-K EDGAR
  5. Aug 1, 20248-K EDGAR
  6. Jun 11, 20243 EDGAR
  7. Jun 11, 2024SC 13D SCHEDULE 13D EDGAR
  8. Jun 4, 20244 EDGAR
  9. Jun 4, 20248-K EDGAR
  10. May 17, 20248-K EDGAR
  11. May 15, 202410-Q EDGAR
  12. May 3, 20248-K EDGAR
  13. Apr 26, 2024UPLOAD EDGAR
  14. Apr 24, 2024CORRESP EDGAR
  15. Apr 24, 202410-K/A EDGAR
  16. Apr 16, 2024UPLOAD EDGAR
  17. Feb 28, 20248-K EDGAR
  18. Feb 27, 202410-Q EDGAR
  19. Feb 15, 2024NT 10-Q EDGAR
  20. Feb 9, 202410-K EDGAR

The 91 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 20, 2022LAIRD NEIL JChief Financial OfficerBuy250,000$0.20$50.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How NovAccess Global Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNovAccess Global Inc.1
  • CIK0001039466
  • Employer ID (EIN)84-13841593
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inColorado3
  • Fiscal year endsSeptember 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address8584 E. Washington Street, No. 127, Chagrin Falls, OH 440231
  • Phone(213) 642-92681
  • Shares outstanding61,652,385 shares as of Jan 14, 20263
  • Public float$337.9K as of Mar 31, 20243
  • AuditorM&K CPAS, PLLC, The Woodlands, Texas PCAOB ID 2738; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceFeb 18, 20001
  • Filings483 in all: 8-K (146), 10-Q (56), NT 10-Q (33), UPLOAD (20), 10-K (19), 10QSB (18), 3 (18), 4 (18)1
    All 44 form types

    NT 10-K (18), CORRESP (13), SC 13D (10), 10-K/A (8), 8-K/A (8), S-1/A (8), 10KSB/A (7), 10KSB (6), 10QSB/A (6), SC 13G/A (6), 424B3 (5), 5 (5), SC 13G (5), 10-Q/A (4), 10SB12G/A (4), EFFECT (4), REGDEX (4), SC 14F1 (4), PRER14A (3), S-1 (3), DEF 14C (2), PRE 14A (2), PRE 14C (2), S-8 (2), SB-2 (2), SB-2/A (2), SC 13D/A (2), SC 14F1/A (2), 10SB12G (1), AW (1), D (1), DEFA14A (1), NT 10-K/A (1), NTN 10K (1), POS AM (1), RW (1)

  • Latest filingsAnnual report (10-K) Jan 14, 2026
    Quarterly report (10-Q) Oct 31, 2024
    Latest 8-K (8-K) Sep 24, 2024

Securities registered for trading

ClassSymbolExchange
None

From the cover page of the 10-K filed Jan 14, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks NovAccess Global Inc. names in Item 1A of its 10-K filed Jan 14, 2026: 41 risks under these headings, as written.3

  • Risks Related to our Business and Operations
  • We do not have the funds needed to continue operations or repay our past due debt.
  • We will need to raise substantial funds, on an ongoing basis, for general corporate purposes and operations, including our clinical trials.
  • TLR-AD1and IDH1 are our only assets in clinical development
  • We are likely to continue to incur substantial losses and may never achieve profitability.
  • Our auditors have issued a “going concern” audit opinion.
  • Our management and our independent auditors have previously identified certain internal control deficiencies which were considered by our management and our independent auditor to be material weaknesses.
  • As a company with a novel technology and unproven business strategy, an evaluation of our business and prospects is difficult.
  • We will need to expand our management and technical personnel as our operations progress, and we may not be able to recruit such additional personnel and/or retain existing personnel.
  • We will rely on third-party contract manufacturers and may be at risk for issues with manufacturing agreements, capacity limitations, supply disruptions, or issues with product equivalency.
  • The manufacturing of our product candidates will have to be greatly scaled up for commercialization, and we do not have this type of experience.
  • The necessary specialized facilities, equipment and personnel may not be available or obtainable for the scale-up of manufacturing of our product candidates.
The other 30 risks
  • Our technology is novel, involves complex immune system elements, and may not prove to be effective.
  • Clinical trials for our product candidates are expensive and time consuming, and their outcome is uncertain.
  • We have limited experience in conducting and managing clinical trials, or collecting, confirming and analyzing trial data, and we rely on third parties to conduct these activities.
  • We may fail to comply with regulatory requirements.
  • Regulatory approval of our product candidates may be withdrawn at any time.
  • The manufacturer and manufacturing facilities we use to make any of our products will also be subject to periodic review and inspection by the FDA or other regulators.
  • We may not be successful in negotiating reimbursement.
  • Our product candidates will require a different distribution model than conventional therapeutic products, and this may impede commercialization of our product candidates.
  • We lack sales and marketing experience, and our product candidates will require different marketing and sales methods and personnel than conventional therapeutic products.
  • The availability and amount of potential reimbursement for our product candidates by government and private payers is uncertain and may be delayed or inadequate.
  • Competition in the biotechnology and biopharmaceutical industry is intense, rapidly expanding and most of our competitors have substantially greater resources than we do.
  • We may be exposed to potential product liability claims, and insurance may not be available or cover these claims.
  • We may be subject to environmental regulatory requirements, and could fail to meet such requirements, and we do not carry insurance against environmental damage or injury claims.
  • Collaborations play an important role in our business and could be vulnerable to competition or termination.
  • Our business could be adversely affected by new legislation or product-related issues.
  • Our business could be adversely affected by animal rights activists.
  • Multiple late-stage clinical trials of TLR-AD1 for glioblastoma, our lead product, and IDH1 companion biomarkers may be required before we can obtain regulatory approval.
  • Changes in manufacturing methods for TLR-AD1 could require us to conduct equivalency studies and/or additional clinical trials.
  • We may not receive regulatory approvals for our product candidates or there may be a delay in obtaining such approvals.
  • We may not maintain the benefits associated with orphan drug status, including market exclusivity.
  • Our intellectual property rights may be overturned, narrowed or blocked, and may not provide sufficient commercial protection for our product candidates, or third parties may infringe upon our intellectual property.
  • We may be exposed to claims or lawsuits that our products infringe patents or other proprietary rights of other parties.
  • Risks Related to Our Company and Stock
  • You may experience dilution of your ownership interests because of the future issuance of additional shares of our common stock for general corporate purposes and upon the exercise of warrants, conversion of convertible debt, or conversion of preferred stock.
  • Our CEO currently has the ability to significantly influence the election of our directors and the outcome of matters submitted to our shareholders.
  • Our articles of incorporation allow for our board to create a new series of preferred stock without further approval by our shareholders, which could adversely affect the rights of the holders of our common stock.
  • Our articles of incorporation and bylaws have provisions that could discourage, delay or prevent a change in control.
  • The market price of our common stock is volatile and can be adversely affected by numerous factors.
  • Our Common Stock is considered a “penny stock” and may be difficult to sell.
  • The requirements of the Sarbanes-Oxley Act of 2002 and other U.S. securities laws impose substantial costs and may drain our resources and distract our management.
  • We do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our stock must come from increases in the market price of our stock.
  • Forward-Looking Statements

Legal proceedings

On October 7, 2024, 13 Paul Lending LLC filed a complaint against NovAccess in the Circuit Court of Fairfax County, Virginia caption 13 Paul Lending LLC v NovAccess Global Inc., CL-2024-0014265. 13 Paul loaned the Company $55,000 pursuant to a securities purchase agreement and convertible promissory note dated August 16, 2023. In the complaint, 13 Paul alleges breach of the note and purchase agreement and is seeking default damages of approximately $510,000. We previously repaid a portion of the loan and believe that the damages sought by 13 Paul are excessive. On October 22, 2025, the court dismissed the case because NovAccess had not been served within a year of 13 Paul filing the complaint. On October 31, 2025, 13 Paul filed a motion for reconsideration, arguing that NovAccess had agreed to accept service. On November 2025, NovAccess made a payment of $10,000 to 13 Paul. We are in ongoing discussions with 13 Paul’s counsel to settle the case, but cannot guarantee that we will be able to settle with 13 Paul on terms acceptable to us or at all.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43